Ravi Salgia

48.7k total citations · 5 hit papers
626 papers, 27.5k citations indexed

About

Ravi Salgia is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ravi Salgia has authored 626 papers receiving a total of 27.5k indexed citations (citations by other indexed papers that have themselves been cited), including 286 papers in Oncology, 263 papers in Molecular Biology and 253 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ravi Salgia's work include Lung Cancer Treatments and Mutations (199 papers), Lung Cancer Research Studies (103 papers) and Liver physiology and pathology (68 papers). Ravi Salgia is often cited by papers focused on Lung Cancer Treatments and Mutations (199 papers), Lung Cancer Research Studies (103 papers) and Liver physiology and pathology (68 papers). Ravi Salgia collaborates with scholars based in United States, India and South Korea. Ravi Salgia's co-authors include Martin Sattler, James D. Griffin, C. Patrick, Gautam Maulik, Jun Gong, James G. Christensen, Alex Chehrazi‐Raffle, Evan Pisick, Aliya N. Husain and Everett E. Vokes and has published in prestigious journals such as Cell, Chemical Reviews and Proceedings of the National Academy of Sciences.

In The Last Decade

Ravi Salgia

610 papers receiving 27.0k citations

Hit Papers

Development of PD-1 and PD-L1 inhibitors as a ... 2011 2026 2016 2021 2018 2012 2011 2024 2025 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
    2018 969 citations Ravi Salgia et al. profile →
  2. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups
    2012 464 citations Ravi Salgia, David J. Sugarbaker et al. profile →
  3. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    2011 445 citations Razelle Kurzrock, Ezra E.W. Cohen et al. profile →
  4. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
    2024 102 citations Prakash Kulkarni, David Horne et al. profile →
  5. Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
    2025 19 citations Pankaj Garg, Meera G. Nair et al. Biochemical Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ravi Salgia United States 90 12.5k 10.6k 8.4k 3.7k 3.2k 626 27.5k
Elizabeth A. Eisenhauer Canada 61 12.0k 1.0× 15.2k 1.4× 12.7k 1.5× 7.3k 2.0× 2.1k 0.7× 213 41.9k
Éric Raymond France 71 8.8k 0.7× 10.9k 1.0× 4.6k 0.5× 3.0k 0.8× 3.1k 1.0× 369 22.4k
Godefridus J. Peters Netherlands 92 18.0k 1.4× 16.5k 1.6× 5.4k 0.6× 5.6k 1.5× 910 0.3× 854 35.0k
Alex A. Adjei United States 78 12.9k 1.0× 11.5k 1.1× 8.2k 1.0× 4.4k 1.2× 828 0.3× 476 26.2k
Howard A. Burris United States 89 13.0k 1.0× 25.4k 2.4× 10.7k 1.3× 6.2k 1.7× 1.2k 0.4× 741 38.2k
David B. Solit United States 82 15.6k 1.3× 10.6k 1.0× 5.6k 0.7× 4.8k 1.3× 684 0.2× 365 26.2k
Jeffrey A. Engelman United States 91 21.3k 1.7× 16.0k 1.5× 13.8k 1.6× 6.2k 1.7× 1.2k 0.4× 187 36.0k
Peter Schirmacher Germany 86 10.9k 0.9× 11.6k 1.1× 6.7k 0.8× 7.6k 2.0× 10.6k 3.4× 681 36.7k
Alberto Bardelli Italy 80 15.7k 1.3× 15.4k 1.4× 7.9k 0.9× 10.3k 2.8× 4.0k 1.3× 264 32.1k
Ming‐Sound Tsao Canada 98 16.5k 1.3× 15.3k 1.4× 13.8k 1.6× 8.3k 2.2× 1.7k 0.5× 653 37.2k

Countries citing papers authored by Ravi Salgia

Since Specialization
Citations

This map shows the geographic impact of Ravi Salgia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi Salgia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi Salgia more than expected).

Fields of papers citing papers by Ravi Salgia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi Salgia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi Salgia. The network helps show where Ravi Salgia may publish in the future.

Co-authorship network of co-authors of Ravi Salgia

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi Salgia. A scholar is included among the top collaborators of Ravi Salgia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi Salgia. Ravi Salgia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garg, Pankaj, Meera G. Nair, Prakash Kulkarni, et al.. (2025). Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy. Biochemical Pharmacology. 236. 116850–116850. 19 indexed citations breakdown →
2.
Subbalakshmi, Ayalur Raghu, Atish Mohanty, Prakash Kulkarni, et al.. (2024). Emerging biomarkers and molecular targets for precision medicine in cervical cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1879(3). 189106–189106. 16 indexed citations
3.
Nickel, Kwangok P., Mari Iida, Prakash Kulkarni, et al.. (2023). Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models. Seminars in Radiation Oncology. 33(3). 279–286.
4.
Strickler, John H., Patricia LoRusso, Ravi Salgia, et al.. (2020). Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 19(5). 1210–1217. 21 indexed citations
5.
Singhal, Sharad S., et al.. (2019). RLIP: An existential requirement for breast carcinogenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1871(2). 281–288. 10 indexed citations
6.
Nardi, Isaac K., Jeremy M. Stark, Adrien Larsen, Ravi Salgia, & Dan J. Raz. (2019). USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks. Molecular Cancer Research. 18(3). 424–435. 16 indexed citations
7.
Brand, Toni M., Mari Iida, Andrew P. Stein, et al.. (2015). AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 21(11). 2601–2612. 89 indexed citations
8.
Brand, Toni M., Mari Iida, Andrew P. Stein, et al.. (2014). AXL Mediates Resistance to Cetuximab Therapy. Cancer Research. 74(18). 5152–5164. 150 indexed citations
9.
Kendra, Kari, Ruth Plummer, Ravi Salgia, et al.. (2014). A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics. 14(2). 461–469. 28 indexed citations
10.
Jardim, Denis L., Chad Tang, Débora De Melo Gagliato, et al.. (2014). Analysis of 1,115 Patients Tested for MET Amplification and Therapy Response in the MD Anderson Phase I Clinic. Clinical Cancer Research. 20(24). 6336–6345. 65 indexed citations
11.
Salgia, Ravi, Premal H. Patel, John Bothos, et al.. (2014). Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 20(6). 1666–1675. 56 indexed citations
12.
Brand, Toni M., Mari Iida, Emily Dunn, et al.. (2014). Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 13(5). 1356–1368. 40 indexed citations
13.
Kawada, Ichiro, Rifat Hasina, Jeffrey Mueller, et al.. (2013). Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer. Cancer Research. 74(3). 884–895. 52 indexed citations
14.
Glubb, Dylan M., Elisa Cerri, Wei Zhang, et al.. (2011). Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer. Clinical Cancer Research. 17(16). 5257–5267. 65 indexed citations
15.
Liu, Wanqing, Lijun He, Jacqueline Ramı́rez, et al.. (2011). Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions. Cancer Research. 71(7). 2423–2427. 36 indexed citations
16.
Liao, Chuanhong, Jinlu Dai, Evan T. Keller, et al.. (2011). Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells. Clinical Cancer Research. 17(10). 3112–3122. 28 indexed citations
17.
Yang, Jianbo, Matt A. Price, Menashe Bar‐Eli, et al.. (2009). Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition. Cancer Research. 69(19). 7538–7547. 79 indexed citations
18.
Seiwert, Tanguy Y., Ramasamy Jagadeeswaran, Leonardo Faoro, et al.. (2009). The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. Cancer Research. 69(7). 3021–3031. 211 indexed citations
19.
Patrick, C., Ramasamy Jagadeeswaran, Simha Jagadeesh, et al.. (2005). Functional Expression and Mutations of c-Met and Its Therapeutic Inhibition with SU11274 and Small Interfering RNA in Non–Small Cell Lung Cancer. Cancer Research. 65(4). 1479–1488. 467 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth A. Eisenhauer Breakdown of academic impact, for papers by Éric Raymond Breakdown of academic impact, for papers by Godefridus J. Peters Breakdown of academic impact, for papers by Alex A. Adjei Breakdown of academic impact, for papers by Howard A. Burris Breakdown of academic impact, for papers by David B. Solit Breakdown of academic impact, for papers by Jeffrey A. Engelman Breakdown of academic impact, for papers by Peter Schirmacher Breakdown of academic impact, for papers by Alberto Bardelli Breakdown of academic impact, for papers by Ming‐Sound Tsao
Rankless by CCL
2026